I am in total agreement with you across the board.
The
I am in total agreement with you across the board.
The one area I want to stress for possible new eyes is your reference to the value you came up with for IPIX should Brilacidin become the "Gold Standard Treatment for CV19" and which you posted within the last number of months.
Your value was based on extremely conservative values for all factors relating to IPIX/CV and the value at which you arrived was JUST for treatment in the USA. Note that "new eyes" - it was ONLY for treatment in the USA. Extrapolate out what it would become if you add in the rest of the world and when you do have some oxygen ready.
When you made this original "value" post we were much earlier in having such positive expectations that Brilacidin would reach the point it is today with the published SI of 426, near 100% viral kill w/ Rem...., and the belief by some in the virology field that believe it has the possibility to become the world's greatest treatment for ALL viruses. Will it reach this pinnacle, who knows, but the RBL test results show it is a serious contender for such a finding.
The point I am trying to make is that some "new eyes" may get glassy at mentions of $20,30, 50 per share but in reality the upper end value is currently in the strong triple digit range when you look at Brilacidin and the TOTAL REVENUE STREAMS it could/will be addressing across the many broad spectrums that we already know it will address (IBD, GI tract in toto, pulmonary to include COPD/Athsma/Bronchitis/others, kidney, encephalitic issues, dermatology uses, etc) and the many additonal uses not currently known or only thought to be possible uses such as cystic fibrosis and for which further testing will have to be done to proceed any further than just the discussion phase.
The financial position of IPIX at the start of the the year made all these opportunities look like merely dreams, but today's financial condition and the expectation of many near term grants and collaborations with possible partners and drugs makes the future look extremely positive that all these indications will be able to be addressed and possibly brought to the stage of being able to help mankind.
I am not giving any upper end numbers as we are not there yet. But be aware that unloading all your shares once a hefty share price is reached (and hefty to you today may be anything over $10 to $50) would be quite profitable but in the long run very foolish.
Know what you own. Know that all current stock pricing is artificially tanked at the current time and that we are on the doorstep of bringing into the headlights of mainstream medicine perhaps the greatest drug ever developed. Not there yet but indications seem to indicate Brilacidin is the real deal.
As a final statement of fact that such a scenario as described above could happen, Regeneron is one of the newest BPs (hint: look up it's share price) and all it had when it started was thalidomide (yes, the drug that deformed all the babies back in the 60s or so) and it built a fortune around this drug and it's many positive abilities (just don't give it to pregnant women). I believe Brilacidin dwarfs thalidomide in comparative abilities so our potential is much greater. Just something to keep in mind.
KNOW WHAT YOU OWN
16
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...
Continue Reading
A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...
Continue Reading
A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...
Continue Reading
A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...
Continue Reading
A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...
Continue Reading
A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...
Continue Reading
Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...
Continue Reading
A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...
Continue Reading
Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...
Continue Reading
A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...
Continue Reading
Top 5 Most Recently Viewed Articles
You know, every now and then, a glimmer of potential bites back against the usual cancer battle headlines. Today, Curis, Inc. (NASDAQ: CRIS) is that flickering hope in the often murky world of biotech, making moves to stir things up with its TakeAim CLL study. Let's do a deep dive into exactly what this could mean for the world battling chronic lymphocytic leukemia....
Continue Reading
Antimicrobial Coating Market Predicted to Surge The Global antimicrobial coating market is on track for remarkable growth, projected to reach US$ 8.82 billion by 2031 from US$ 3.78 billion in 2023. This substantial growth corresponds to a compound annual growth rate (CAGR) of 11.2% throughout the forecast period. Growing Demand for Antimicrobial Coatings One of the...
Continue Reading
Recent Transactions by Management at Royal Unibrew A/S Royal Unibrew A/S, a prominent player in the beverage industry, has recently made important disclosures regarding share transactions executed by its key management personnel. This announcement is made in accordance with the regulations aimed at promoting transparency in the market. Transaction Details Overview This...
Continue Reading
Innovative Design for Racing Safety Recently, a creative inventor conceptualized an advanced support post specifically for horse racing track railings. This inventive solution was born from a desire to lessen the risk of injury to jockeys and horses. The inventor aimed to create a product that enhances safety on race tracks while providing peace of mind for everyone...
Continue Reading
Aurigo Software Partners with Philadelphia for Infrastructure Growth Aurigo Software, known for its expertise in capital planning and construction management, has announced a significant partnership with the City of Philadelphia. This multiyear contract aims to leverage Aurigo's leading product suite, Masterworks, to improve infrastructure program management for the city....
Continue Reading